Leyden Labs is a biotechnology startup that operates in the healthcare sector, specifically focusing on the prevention of respiratory viruses. The company is developing nasal sprays that contain antibodies targeting these viruses at their point of entry - the nasal mucosa. This innovative approach aims to curb the spread of viruses, including those that are asymptomatic, by stopping infections early on.

The company's products are based on a robust scientific platform that leverages mucosal immunity and broad protection. The nasal sprays deliver antibodies directly to the nasal mucosa, providing immediate anti-viral protection to the user. This method is believed to be more effective than systemic administration, as it allows the antibodies to efficiently target invading virus particles in the complex environment of the nasal mucosa.

Leyden Labs' business model involves partnering with leading intranasal formulation and device companies to optimize the delivery of these intranasally-administered antibodies. The company is also at the forefront of antibody modification for mucosal administration, a critical aspect given the high rate of evolution of respiratory viruses.

The company's primary clients are individuals at risk of contracting respiratory viruses, including influenza and COVID-19. By offering a preventative solution, Leyden Labs is addressing a significant global health issue and preparing us for future endemic and pandemic threats.

In terms of revenue generation, Leyden Labs likely makes money by selling its nasal sprays to consumers, either directly or through healthcare providers. The company may also generate income through partnerships with other companies in the healthcare sector.

Keywords: Biotechnology, Healthcare, Respiratory Viruses, Nasal Sprays, Antibodies, Mucosal Immunity, Broad Protection, Intranasal Formulation, Antibody Modification, Pandemic Prevention.